trial summary · NCT07516366
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Clear Cell Renal Cell Carcinoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell cancer that has not spread from where it first started to other areas of the body (non-metastatic). The current standard treatment for patients with non-metastatic clear cell renal cell cancer may include surgery to completely remove the tumor. This typically involves removing the kidney or part of the kidney (nephrectomy). Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving neoadjuvant botensilimab and balstilimab may be safe, tolerable, and/or effective in treating patients with high-risk non-metastatic clear cell renal cell cancer before undergoing a nephrectomy.
Source record: https://clinicaltrials.gov/study/NCT07516366
Facts
| registry id | NCT07516366 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Clear Cell Renal Cell Carcinoma |
| sponsor | National Cancer Institute (NCI) |
| sponsor class | NIH |
| enrollment | 16 |
| start date | 2027-05-17 |
| primary completion | 2028-12-31 |
| completion | 2028-12-31 |
| results posted | not reported |
Conditions
- Clear Cell Renal Cell Carcinoma
- Stage II Renal Cell Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
Interventions
- Balstilimab
- Biospecimen Collection
- Botensilimab
- Computed Tomography
- Nephrectomy
- Questionnaire Administration
Countries
- United States
Intervention types: BIOLOGICAL, OTHER, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.